Should only be used if no suitable treatment alternatives are available in patients ≥65 yr; patients w/ history of atherosclerotic CV disease or other CV risk factors (eg, current or past long-time smokers); patients w/ malignancy risk factors (eg, current or history of malignancy). Discontinue treatment in case of clinically significant hypersensitivity reaction. Reports of serious & sometimes fatal infections; viral reactivation; lymphoma & other malignancies; non-melanoma skin cancer; haematological abnormalities; diverticulitis & GI perforations; VTE. Interrupt therapy if patient develops a serious or opportunistic infection. Screen patients for TB before starting therapy & monitor for development of TB signs & symptoms during therapy, including patients who tested -ve for latent TB infection prior to initiating therapy. Screen patients for viral hepatitis & monitor for reactivation before starting treatment & during therapy. Not recommended to use live, attenuated vaccines during or immediately prior to therapy. Bring patients up to date w/ all immunisations, including prophylactic zoster vaccinations, prior to treatment initiation. Periodic skin exam is recommended for all patients, particularly those w/ risk factors for skin cancer. Do not initiate or temporarily interrupt treatment in patients w/ ANC <1 x 10
9 cells/L, absolute lymphocyte count <0.5 x 10
9 cells/L or Hb <8 g/dL. Increased lipid parameters, including total, LDL & HDL cholesterol. Increased incidence of liver enzyme elevation. Not recommended to combine w/ other potent immunosuppressants (eg, azathioprine, 6-mercaptopurine, ciclosporin, tacrolimus, & biologic DMARDs or other JAK inhibitors). Caution in patients w/ severe renal impairment. Not recommended in patients w/ end stage renal disease. Women of childbearing potential should use effective contraception during treatment & for 4 wk following final dose. Should not be used during breast-feeding. RA, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, Crohn's disease: Safety & efficacy have not been established in childn & adolescent <18 yr. Atopic dermatitis: Safety & efficacy have not been established in childn <12 yr; adolescent weighing <40 kg.